about
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway.CRISPR-Cas-related technologies in basic and translational liver research.Use of the CRISPR/Cas9-Based Epigenetic Gene Activation System in Vivo: a New Potential Therapeutic Modality.
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
CRISPR/Cas9: at the cutting edge of hepatology.
@en
CRISPR/Cas9: at the cutting edge of hepatology.
@nl
type
label
CRISPR/Cas9: at the cutting edge of hepatology.
@en
CRISPR/Cas9: at the cutting edge of hepatology.
@nl
prefLabel
CRISPR/Cas9: at the cutting edge of hepatology.
@en
CRISPR/Cas9: at the cutting edge of hepatology.
@nl
P2093
P2860
P1433
P1476
CRISPR/Cas9: at the cutting edge of hepatology
@en
P2093
Francis P Pankowicz
Karl-Dimiter Bissig
William R Lagor
P2860
P304
P356
10.1136/GUTJNL-2016-313565
P407
P577
2017-05-09T00:00:00Z